AUTM Newsbrief
Dec. 15, 2011

Neoprobe licenses AstraZeneca's Alzheimer plaque imaging agent
Genetic Engineering & Biotechnology News
Neoprobe paid AstraZeneca $5 million up front for a license to the latter's late-stage radiopharmaceutical imaging candidate AZD4694, for use in positron emission tomography diagnostic imaging of amyloid plaques in Alzheimer disease patients. Under terms of the deal Neoprobe will take on clinical development and commercialization of the fluorine-18-labelled radiotracer, and expects to start a Phase III clinical program during early 2013.More

Long-lasting all-weather night-vision material unveiled
BBC News
A U.S.-based team of scientists claims to have invented a material that releases over two weeks of night-vision light after just one minute's exposure to the sun. The University of Georgia team says the near-infrared emitting substance could offer the military "secret" illumination at nighttime. It says the all-weather material could also revolutionize diagnostic medicine. The details are published in the latest issue of the Nature Materials journal.More

European Union ban on stem cell patents is a threat both to science and the rule of law
The Guardian
The full implications of the recent ban on stem cell patents by the Grand Chamber of the Court of Justice of the European Union could take a long time to assess. From a legal perspective, the court's ruling is seriously flawed. In a case brought by Greenpeace against the German neuroscientist Oliver Bruestle, the EU court controversially ruled that an unclear and much litigated prohibition in EU patent law on "commercial and industrial uses of human embryos" applies to therapeutic products and therapies containing embryonic cells when the derivation of the cells or lines originally required the destruction of human embryos.More

Patent license agreement between Applied Precision, Yale expands TIRF capabilities
BioOptics World
Applied Precision has licensed exclusive patents from Yale University, allowing the company to integrate enhanced total internal reflection fluorescence microscopy into its existing product suite. Known as Ring-TIRF microscopy, the technology illuminates samples with TIRF as an adjustable ring of light, removing interference fringes and allowing fast multi-angle illumination to correct for chromatic differences and 3-D illumination of the cell cortex. The technology also provides modality for fluorescence recovery after photobleaching and photoactivation.More

Study: Heart drug may be effective for managing certain cancers
HealthCanal.com
Researchers at Queen's University have identified a new mechanism that could potentially explain why the body's immune system sometimes fails to eliminate cancer. The new findings shed light on the possible cause of immune resistance in cancer cells, and indicate that nitroglycerin, a relatively safe and low-cost drug used for more than a century to treat angina, may be effective for managing certain cancers. More than 10 patents have been issued to Queen's research discoveries involving the the use of nitroglycerin and similar compounds in cancer treatments. PARTEQ Innovations, the technology transfer office of Queen's, has licensed some of this intellectual property to Nometics Inc., a Queen's spinoff company, which is developing products and therapies based on this and related research.More

Nanoparticles carting steroids to retina delay macular degeneration
FierceDrugDelivery
Researchers have developed a sustained-release drug delivery system that successfully brought steroids to the retina to treat degenerative eye conditions. Nanoparticles known as dendrimers gave the treatment a ride in. Details of the study — developed by researchers from Wayne State University, the Mayo Clinic and The Wilmer Eye Institute of Johns Hopkins — are published in the journal Biomaterials. Scientists believe that the treatments could offer a targeted, sustained release drug treatment for both age-related macular degeneration and retinitis pigmentosa. More

University of Minnesota will give intellectual property rights to industry research partners
Minnesota Public Radio
The University of Minnesota plans to forgo its intellectual property rights when partnering with industry on research. U of M officials say contentious negotiations over who owns the rights to sell technology and products developed during industry-funded research has derailed a number of partnerships. Changing how it partners with business and industry. The university now proposes that industries that approach with research funding and pay a one-time fee (amounting to 10 percent of their research funding) can in return keep the intellectual property rights to any products or technology that result from the partnership. More

AUTM | Member benefits
AUTM
AUTM would like to express our appreciation to organizations that encourage their technology transfer professionals to join AUTM and receive the many benefits of membership. Read about how your organization can benefit from the AUTM Membership Appreciation Program.More